Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reiterated at Cowen and Company
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reiterated by Cowen and Company in a note issued to investors on Wednesday. They presently have a $117.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $93.00. Cowen and Company’s target price suggests a potential upside of 2.83% from the stock’s previous close.
Several other research firms also recently weighed in on ALNY. Jefferies Group LLC set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Barclays PLC upped their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 10th. Credit Suisse Group upped their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 27th. BMO Capital Markets restated an “outperform” rating and set a $99.00 price target (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Finally, Leerink Swann restated a “market perform” rating and set a $72.00 price target (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $87.59.
Shares of Alnylam Pharmaceuticals (ALNY) traded up 51.71% on Wednesday, hitting $113.84. The stock had a trading volume of 18,362,421 shares. The firm’s 50-day moving average price is $81.14 and its 200 day moving average price is $69.12. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $116.93. The firm’s market cap is $10.44 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same quarter last year, the company earned ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $148,000. QS Investors LLC boosted its position in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 900 shares during the period. Westpac Banking Corp purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $202,000. The Manufacturers Life Insurance Company boosted its position in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $215,000. 94.25% of the stock is owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.